Every treatment that has ever made a difference in cancer care was once a part of a clinical trial. MUSC Hollings Cancer Center is committed to offering the best treatments available today while searching for even better ones for the future. Ask your doctor if a clinical trial is right for you.
STUDY17022 First in Human, Phase 1/1b, Open label, Multicenter Study of Bifunctional EGFR/TGF ß Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR Driven Advanced Solid Tumors The investigational drug to be studied in this protocol, BCA101, is a first-in-class compound that targets both EGFR with TGFβ. Based on preclinical data, this bifunctional antibody may exert synergistic activity in patients with EGFR-driven tumors. Study Information
STUDY23589 A Phase 1 Open Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications To assess the efficacy of ABBV-400 in each solid tumor indication, including advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC and HNSCC. To characterize the safety and tolerability of ABBV-400 as monotherapy in advanced or metastatic HCC, BTC, PDAC, ESCC, TNBC, HR+/HER2- BC, and HNSCC. Study Information